IMTX Dec 2025 12.500 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 03:48PM EDT. Market open.
Loading interactive chart...
- Simply Wall St.
Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns
Key Insights Immatics' Annual General Meeting to take place on 20th of June Total pay for CEO Harpreet Singh includes...
- Simply Wall St.
Here's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GlobeNewswire
Immatics Announces First Quarter 2024 Financial Results and Business Update
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, including tumor shrinkage achieved in 87% of patients; median duration of response of 13.5 months including 11/16 ongoing confirmed responses; IMA203 continues to maintain a favorable safety profileRegistration-enabling
© 2024 Yahoo. All rights reserved.